<DOC>
	<DOCNO>NCT02893618</DOCNO>
	<brief_summary>Open label , parallel-group , single site , 5 treatment-period study 4 dose level DCCR , 1 administer without food .</brief_summary>
	<brief_title>A 5 Treatment Period Pharmacokinetic Study Evaluating Dose Proportionality Food Effects Diazoxide Choline Controlled-Release Tablet ( DCCR )</brief_title>
	<detailed_description>Open label , parallel-group , single site , 5 treatment-period study 4 dose level DCCR , 1 administer without food , 10 Day washout period treatment . There 8 treatment sequence 4 subject randomize .</detailed_description>
	<mesh_term>Prader-Willi Syndrome</mesh_term>
	<mesh_term>Choline</mesh_term>
	<mesh_term>Diazoxide</mesh_term>
	<criteria>Ability follow verbal write instruction Informed consent form sign subject Completed screening within 7 day prior dose BMI 18.5 35 kg/m2 Generally healthy fast glucose less equal 100 mg/dL HbA1c le equal 6 % Pregnancy breast feed absence contraception administration investigational drug within 1 month prior screen anticipate requirement prohibit medication ( systemic corticosteroid antidiabetic medication ) allergic reaction significant intolerance diazoxide , thiazide sulfonamide know type 1 type 2 diabetes mellitus congestive heart failure gastric bypass surgery history drug alcohol abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>